OncoMatch/Clinical Trials/NCT05295212
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
Is NCT05295212 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Atezolizumab for non small cell lung cancer.
Treatment: Atezolizumab — This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: EGFR mutation
if they test positive for EGFR ... they are considered as exclusion criteria; if they are adenocarcinoma, they must undergo genetic testing containing at least EGFR, ALK and ROS1
Excluded: ALK fusion
if they test positive for ... ALK ... they are considered as exclusion criteria; if they are adenocarcinoma, they must undergo genetic testing containing at least EGFR, ALK and ROS1
Excluded: ROS1 fusion
if they test positive for ... ROS1, they are considered as exclusion criteria; if they are adenocarcinoma, they must undergo genetic testing containing at least EGFR, ALK and ROS1
Disease stage
Required: Stage II, IIIA, IIIB (N2) (AJCC stage VIII)
Excluded: Stage IIIC
resectable stage II, IIIA, IIIB (N2) (AJCC stage VIII) NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic anticancer therapy
Early stage NSCLC previously treated with systemic anticancer therapy, including treatment with investigational agents
Cannot have received: PD-1/PD-L1 inhibitor or other T cell receptor targeting drug
Previous treatment with PD-1/PD-L1 drugs or treatment with another drug targeting T cell receptor (such as CTLA-4, OX-40, etc.)
Lab requirements
Blood counts
absolute neutrophil count (anc) ≥ 1500/μl; platelets ≥ 100,000/μl; hemoglobin ≥ 9.0 g/dl or ≥ 5.6 mmol/l
Kidney function
serum creatinine ≤ 1.5 times uln or calculated creatinine clearance (crcl) ≥ 60 ml/min (using the cock-gault formula)
Liver function
total bilirubin ≤ 1.5 × uln or for subjects with total bilirubin levels > 1.5 × uln, direct bilirubin is within normal limits; ast (sgot) and alt (sgpt) ≤ 2.5 × uln
Cardiac function
baseline ecg showed no pr interval prolongation or atrioventricular block
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05295212 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR mutation is an exclusion criterion.
Are patients with ALK alterations eligible?
No. ALK fusion is an exclusion criterion.
What disease stage is eligible?
Stage II or IIIA or IIIB (N2) is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages